Literature DB >> 22158198

Neuroendocrinology: Improved progression-free survival with everolimus plus octreotide in carcinoid syndrome.

Linda Koch.   

Abstract

Entities:  

Year:  2011        PMID： 22158198     DOI： 10.1038/nrendo.2011.230

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Authors:  Marianne E Pavel; John D Hainsworth; Eric Baudin; Marc Peeters; Dieter Hörsch; Robert E Winkler; Judith Klimovsky; David Lebwohl; Valentine Jehl; Edward M Wolin; Kjell Öberg; Eric Van Cutsem; James C Yao
Journal:  Lancet       Date:  2011-11-25       Impact factor: 79.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.